Lifitegrast sodium, also known as SAR-1118, is an LFA-1 antagonist intended for the treatment of vascular complications of the eye.

LMP744(Mj-III-65,NSC-706744) is a DNA intercalator and topoisomerase inhibitor with antitumor activity.

LSN2814617 is a neurotoxic positive allosteric modulator.

LX-2343 is a novel non-ATP competitive PI3K inhibitor, negatively regulating AKT/mTOR signaling, thus promoting autophagy, and increasing A-beta clearance.

Maytansinoid DM4, a chemical derivative of maytansine, is a potent and selective cytotoxic agent with promising anticancer properties. Anticancer properties of maytansinoids have been attributed to their ability to disrupt microtubule function. Maytansin

Methacholine chloride is used to constrict airway smooth muscle and to assess bronchial reactivity. Methacholine chloride is a cholinergic agonist and parasympathomimetic bronchoconstrictor. A metabolically stable analog of acetylcholine, it is a muscarin

Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.

ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases.

P300/CBP-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1[1].

Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC50 of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies.

PF-9363 (CTx-648) is a first-in-class potent and high selective KAT6A/KAT6B inhibitor. PF-9363 can be used for the research ofcancer[1][2]. PF-9363 (0~1 μM; 1 day; ZR75-1, T47D and MCF7 cells) down-regulates the expression of H3K23Ac biomarker[1]. PF-9363

Potent Allosteric Agonist-Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptors

preQ1 is a precursor in the biosynthesis of queuosine, a bacterial nucleoside incorporated into tRNA by tRNA transglycosylase. preQ1 binds to an aptamer domain on tRNA that acts as a riboswitch to repress gene expression.

Sacubitril, also known as AHU377, is angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases. LBQ657 inhibits the e

Zabedosertib (BAY 1834845) is a IRAK4 inhibitor with immunomodulatory potential. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors.

GO289 (GO-289, GO 289) is a potent and selective inhibitor of casein kinase 2 (CK2) with IC50 of 7 nM in in vitro kinase assays, shows minor effects on CKIδ and CKIα activity in vitro.

Cyclo(Gly-Gln) is a cyclic dipeptide.

ANR-94 is a potent and selective adenosine A2A receptor (AA2AR) antagonist with an Ki of 46 nM for hAA2AR. ANR 94 has the potential for the research of Parkinson's disease.

SP-8356, an anti-inflammatory synthetic verbenone derivative, is a potent, orally active cluster of differentiation 147 (CD147) inhibitor. SP-8356 inhibits CD147-cyclophilin A (CypA) interaction and reduces MMP-9 activity. SP-8356 exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects[1][2][3].

Aficamten (CK-274) is a novel cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).

TFMT (Trifluoromethyl-tubercidin) inhibits methyltransferase 1 (MTr1) through interaction at its S-adenosyl-l-methionine binding pocket to restrict influenza virus replication. TFMT is active against influenza A virus (IAV) and influenza B virus (IBV) but not hazara virus (HAZV) or Issyk-Kul virus (ISKV).

DT2216-isomer is an isomer of DT2216. Compared to DT-2216, DT2216-isomer has a S-chiral carbon which links to the nitrogen atom of the aniline group. DT2216 is a potent and selective Bcl-xL-specific degrader. DT2216 is highly active against Bcl-xL-dependent T cell lymphomas. DT2216 selectively killed various Bcl-xL-dependent TCL cells including MyLa cells in vitro. In vivo, DT2216 alone was highly effective against MyLa TCL xenografts in mice without causing significant thrombocytopenia or other toxicity. Furthermore, DT2216 combined with ABT199 (a selective Bcl-2 inhibitor) synergistically reduced disease burden and improved survival in a TCL PDX mouse model dependent on both Bcl-2 and Bcl-xL.

H-7 is a specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.

VUN74640, also known as CCR6 antagonist 1, is a CCR6 antagonist. VUN74640 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs). This product has no formal name at the moment.

STD-101-D1 is a novel brain permeable, G protein-biased beta-1 adrenergic receptor (ADRB1) partial agonist with EC50 of 16.9 nM.